Capital International Sarl Sells 8,341 Shares of Boston Scientific Corporation $BSX

Capital International Sarl cut its position in shares of Boston Scientific Corporation (NYSE:BSX) by 2.5% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 328,291 shares of the medical equipment provider’s stock after selling 8,341 shares during the period. Capital International Sarl’s holdings in Boston Scientific were worth $32,051,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Vanguard Group Inc. raised its stake in shares of Boston Scientific by 0.8% in the 3rd quarter. Vanguard Group Inc. now owns 138,249,447 shares of the medical equipment provider’s stock valued at $13,497,294,000 after buying an additional 1,115,337 shares in the last quarter. State Street Corp boosted its holdings in Boston Scientific by 1.1% during the second quarter. State Street Corp now owns 65,191,864 shares of the medical equipment provider’s stock valued at $7,002,258,000 after purchasing an additional 713,379 shares in the last quarter. Geode Capital Management LLC grew its stake in shares of Boston Scientific by 2.0% in the 2nd quarter. Geode Capital Management LLC now owns 32,424,982 shares of the medical equipment provider’s stock valued at $3,466,320,000 after purchasing an additional 622,602 shares during the period. Norges Bank bought a new stake in shares of Boston Scientific in the 2nd quarter valued at approximately $2,089,937,000. Finally, Invesco Ltd. raised its holdings in shares of Boston Scientific by 1.4% in the 2nd quarter. Invesco Ltd. now owns 16,851,518 shares of the medical equipment provider’s stock worth $1,810,022,000 after buying an additional 226,578 shares in the last quarter. 89.07% of the stock is owned by institutional investors.

Boston Scientific News Roundup

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Company actions that may support the share price: Boston Scientific negotiated a new $3.0 billion revolving credit facility (matures 2031), expanded its share‑repurchase authorization to $5.0 billion, and added two senior healthcare/finance leaders to the board — moves that can bolster liquidity and signal confidence in capital returns. Is Boston Scientific (BSX) Balancing Buybacks and Litigation or Masking Deeper Electrophysiology Risks?
• Neutral Sentiment: Options activity: traders bought ~23,040 put contracts on Monday — roughly a 27% increase vs. typical daily put volume — indicating elevated hedging or bearish interest but not a definitive directional signal by itself.
• Negative Sentiment: Legal and regulatory risk escalating: multiple law firms (Rosen, Levi & Korsinsky, Robbins, Bronstein, Schall, Faruqi & Faruqi) have filed or announced investigations and class actions on behalf of BSX investors covering the July 23, 2025–Feb 3, 2026 period; lead‑plaintiff deadlines have been set (May 4, 2026 in several notices). The suits and media coverage cite a Class I recall of the AXIOS Stent & Delivery System, a federal probe of disclosures/product safety, and allegations of misleading statements about the U.S. electrophysiology business — risks that could lead to settlements, fines, or reputational damage and weigh on earnings and cash flow. Shareholders of Boston Scientific Corporation Should Contact Levi & Korsinsky Boston Scientific Recall And Lawsuits Test Earnings Power And Capital Plans

Insider Activity

In related news, CEO Michael F. Mahoney sold 160,901 shares of the firm’s stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $93.49, for a total value of $15,042,634.49. Following the transaction, the chief executive officer owned 1,411,735 shares in the company, valued at $131,983,105.15. This trade represents a 10.23% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.50% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Several analysts recently commented on the company. Barclays decreased their price target on Boston Scientific from $136.00 to $124.00 and set an “overweight” rating on the stock in a research note on Tuesday, February 3rd. UBS Group reduced their target price on shares of Boston Scientific from $140.00 to $120.00 and set a “buy” rating on the stock in a research note on Thursday, February 5th. Sanford C. Bernstein reiterated an “outperform” rating and set a $112.00 target price on shares of Boston Scientific in a research report on Friday, February 6th. Stifel Nicolaus reduced their price target on shares of Boston Scientific from $125.00 to $110.00 and set a “buy” rating on the stock in a research report on Wednesday, February 4th. Finally, Oppenheimer cut their target price on shares of Boston Scientific from $125.00 to $100.00 and set an “outperform” rating for the company in a research note on Friday, January 16th. Two investment analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat.com, Boston Scientific has an average rating of “Moderate Buy” and an average target price of $108.36.

Boston Scientific Price Performance

BSX opened at $71.88 on Tuesday. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.62 and a quick ratio of 1.08. The stock has a market capitalization of $106.66 billion, a P/E ratio of 37.05, a price-to-earnings-growth ratio of 1.00 and a beta of 0.69. The company’s 50 day simple moving average is $84.55 and its 200-day simple moving average is $94.24. Boston Scientific Corporation has a one year low of $69.52 and a one year high of $109.50.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings data on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share for the quarter, topping the consensus estimate of $0.78 by $0.02. The firm had revenue of $5.29 billion during the quarter, compared to analysts’ expectations of $5.29 billion. Boston Scientific had a net margin of 14.44% and a return on equity of 19.63%. Boston Scientific’s revenue was up 15.9% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.70 EPS. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. Sell-side analysts anticipate that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.